2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid is a complex heterocyclic compound featuring a fused pyrimido[5,4-f][1,4]oxazepine core linked to a trans-cyclohexylacetic acid moiety via a phenyl bridge. This structure is a key synthetic intermediate in medicinal chemistry. This compound is a crucial intermediate in the synthesis of advanced pharmaceutical agents. It is specifically utilized in the preparation of potent and selective inhibitors targeting the phosphatidylinositol 3-kinase (PI3K) pathway, particularly PI3Kδ. The PI3Kδ isoform plays a significant role in B-cell signaling and survival, making it a validated target for the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphoma. The structural complexity of this intermediate allows for the precise construction of the pharmacophore necessary for high-affinity target binding. As a high-value pharmaceutical intermediate, its synthesis and purity are critical for the downstream production of active pharmaceutical ingredients (APIs) in oncology drug development pipelines. Handling requires standard laboratory precautions for fine chemicals.